• Journal of The Korean Society of Grassland and Forage Science
• /
• v.40 no.1
• /
• pp.66-72
• /
• 2020

This study aimed to discuss the optimal seeding and harvesting dates with growing degree days(GDD) via meta-data of whole crop maize(WCM). The raw data (n=3,152) contains cultivation year, cultivars, location, seeding and harvesting dates collected from various reports such as thesis, science journals and research reports (1982-2012). The processing was: recording, screening and modification of errors; Then, the final dataset (n=121) consists of seeding cases (n=29), and harvesting cases (n=92) which were used to detect the optimum. In addition, the optimal periods considering tolerance range and GDD also were estimated. As a result, the optimum seeding and harvesting periods were 14th April ~ 3rd May and 15th August ~ 4th September, respectively; where, their GDDs were 23.7~99.6℃ and 1,328.7~1,602.1℃, respectively. These GDDs could be used as a judge standard for selecting the seeding and harvesting dates.

• Journal of The Korean Society of Integrative Medicine
• /
• v.9 no.3
• /
• pp.87-97
• /
• 2021

Purpose : The purpose of this meta-analysis was to evaluate the effects of transcranial direct current stimulation on the lower extremity function of stroke patients. Methods : Domestic data were gathered from studies that conducted clinical trials associated with transcranial direct current stimulation and its impact on lower extremity function of stroke patients. A total of 592 studies published between 2012 and 2020 were identified, with 7 studies satisfying the inclusion data. The studies consisted of patient, intervention, comparison, and outcome (PICO) data. The search outcomes were items associated with muscle activity, balance, muscle strength and walking ability. Cochrane risk of bias (ROB) was used to evaluate the quality of 3 randomized control trials. The quality of 4 non-randomized control trials was evaluated using risk of bias assessment tool for non-randomized studies (RoBANS). Effect sizes in this study were computed as the corrected standard mean difference (SMD). A random-effect model was used to analyze the effect size because of the high heterogeneity among the studies. Egger's regression and 'trim-and-fill' tests were carried out to analyze the publishing bias. Results : The following factors had a large total effect size (Hedges's g=2.10, 95 %CI=1.54~2.66) involving transcranial direct current stimulation on stroke patients: muscle activity (Hedges's g=2.38, 95 %CI=1.08~3.68), balance (Hedges's g4=2.41, 95 %CI=1.33~3.60), walking ability (Hedges's g=1.54, 95 %CI=0.49~2.59), and muscle strength (Hedges's g=2.45, 95 % CI: 0.85~4.05). Egger's regression test showed that the publishing bias had statistically significant differences but 'trim-and-fill' test showed that there was still statistical difference. Conclusion : This study provides evidence for the effectiveness of transcranial direct current stimulation on the lower extremity in terms of muscle activity, balance, walking ability, and muscle strength in stroke patients. However, due to the low quality of studies and high heterogeneity factors, the results of our study should be interpreted cautiously.

• Journal of Preventive Medicine and Public Health
• /
• v.57 no.4
• /
• pp.327-338
• /
• 2024

Objectives: Estimating the number of deaths caused by smoking is crucial for developing and evaluating tobacco control and smoking cessation policies. This study aimed to determine smoking-attributable mortality (SAM) in Korea in 2020. Methods: Four large-scale cohorts from Korea were analyzed. A Cox proportional-hazards model was used to determine the hazard ratios (HRs) of smoking-related death. By conducting a meta-analysis of these HRs, the pooled HRs of smoking-related death for 41 diseases were estimated. Population-attributable fractions (PAFs) were calculated based on the smoking prevalence for 1995 in conjunction with the pooled HRs. Subsequently, SAM was derived using the PAF and the number of deaths recorded for each disease in 2020. Results: The pooled HR for all-cause mortality attributable to smoking was 1.73 for current men smokers (95% confidence interval [CI], 1.53 to 1.95) and 1.63 for current women smokers (95% CI, 1.37 to 1.94). Smoking accounted for 33.2% of all-cause deaths in men and 4.6% in women. Additionally, it was a factor in 71.8% of men lung cancer deaths and 11.9% of women lung cancer deaths. In 2020, smoking was responsible for 53 930 men deaths and 6283 women deaths, totaling 60 213 deaths. Conclusions: Cigarette smoking was responsible for a significant number of deaths in Korea in 2020. Monitoring the impact and societal burden of smoking is essential for effective tobacco control and harm prevention policies.

• Clinical Nutrition Research
• /
• v.11 no.4
• /
• pp.302-315
• /
• 2022

The present systematic review and meta-analysis were conducted in order to investigate the effects of capsinoids and fermented red pepper paste (FRPP) supplementation on lipid profile. Relevant studies were identified by searches of five databases from inception to November 2021 using relevant keywords. All clinical trials investigating the effect of capsinoids and FRPP on total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C) were included. Out of 1,203 citations, eight trials that enrolled 393 participants were included. Capsinoids and FRPP resulted in a significant reduction in TC (weighted mean differences [WMD], -9.92 mg/dL; 95% confidence interval [CI], -17.92 to -1.92; p = 0.015) but no significant changes in TG (WMD, -19.38 mg/dL; 95% CI, -39.94 to 1.18; p = 0.065), HDL-C (WMD, 0.83 mg/dL; 95% CI, -0.76 to 2.42; p = 0.305) and LDL-C (WMD, -0.59 mg/dL; 95% CI, -4.96 to 3.79; p = 0.793). Greater effects on TC were detected in trials performed on duration lasting less than twelve weeks, mean age of > 40, both sexes, and sample size of > 50. TG was reduced by using FRPP in studies conducted on mean age of > 40. HDL-C increased by using FRPP in studies conducted on duration of < 12 weeks, mean age of > 40, and sample size of ≤ 50. Overall, these data provided evidence that capsinoids and FRPP supplementation has beneficial effects on TC but not TG, HDL-C, and LDL-C.

• The Journal of Internal Korean Medicine
• /
• v.45 no.4
• /
• pp.726-743
• /
• 2024

Objectives: This study was conducted to evaluate the effectiveness of the combination therapy of Saengmaek-san decoction and Western medicine on heart failure. Methods: A search was conducted on June 22, 2024 using keywords such as "heart failure", "saengmaeksan", and "shengmaisan". A meta-analysis was conducted according to the outcome measurements such as the total effective rate (TER), serum B-type natriuretic peptide (BNP), echocardiography results (left ventricular ejection fraction (LVEF), left ventricular end-diastolic diameter (LVEDD), left ventricular end-systolic diameter (LVESD), stroke volume (SV)), and six-minute walk test (6MWT). Data analysis was performed using the RevMan 5.4.1 software, and Cochrane's risk of bias (ROB) was used to assess the quality of the papers. Results: A total of eight randomized control trials were selected. The treatment group combining Saengmaek-san and Western medicine showed significant improvement effects in terms of TER, BNP, LVEF, LVESD, LVEDD, SV, and 6MWT compared to the control group using Western medicine alone [TER] RR=1.23, 95% CI: 1.13-1.34, p<0.00001; [BNP] MD=-206.14, 95% CI : -257.49--154.79, p<0.00001; [LVEF] MD=6.40, 95% CI : 5.54-7.27, p<0.00001; [LVEDD] MD=-6.55, 95% CI : -7.24--5.85, p<0.00001; [LVESD] MD=-3.07, 95% CI: -3.92--2.22, p<0.00001; [SV] MD=7.12, 95% CI : 5.73-8.50, p<0.00001; [6MWT] MD=43.69, 95% CI : 31.55-55.84, p<0.00001. Conclusion: This study suggests that the combination therapy of Saengmaek-san decoction and Western medicine is effective in treating heart failure. However, these findings should be interpreted cautiously due to the unknown or high risk of bias in the included trials.

• Asian Pacific Journal of Cancer Prevention
• /
• v.13 no.12
• /
• pp.6227-6232
• /
• 2012

Interleukin-4 receptor (IL-4R) gene single nucleotide polymorphisms (SNPs) are implicated in cancer development. However, results from the published reports have remained inconclusive. The objective of this study was to conduct a meta-analysis investigating the association between polymorphisms in IL-4R gene and cancer risk. Pubmed, EMBASE and China National Knowledge Infrastructure (CNKI) were searched for case-control studies published up to October 30, 2012 that investigated IL-4R polymorphisms and cancer risk. Odds ratios (ORs) and 95% confidence intervals (CIs) were used to evaluate the strength of any associations. Three IL-4R polymorphisms (Q576R, rs1801275; I75V, rs1805010; S503P, rs1805015) in 21 case-control studies were analyzed. Our meta-analysis indicated that these three polymorphisms are not associated with cancer risk when all studies were pooled together. In the subgroup analysis by tumor site, the results showed that Q576R G allele carriers were associated with a significantly decreased cervical cancer risk (recessive model: OR = 0.77, 95%CI = 0.60-0.98; homozygote comparison: OR = 0.76, 95%CI = 0.58-0.98). I75V G allele carriers were associated with a decreased risk of renal cancer (dominant model = 0.71, 95%CI = 0.57-0.89, heterozygote comparison: OR = 0.69, 95%CI = 0.55-0.87). When stratified by ethnicity, Q576R G allele carriers were associated with a decreased cancer risk in Caucasians (dominant model: OR = 0.90, 95%CI = 0.83-0.98; heterozygote comparison: OR = 0.89, 95%CI = 0.82-0.98). I75V G allele carriers were associated with a decreased cancer risk in Asians (heterozygote comparison: OR = 0.76, 95%CI = 0.62-0.94). S503P C allele carriers were also associated with a decreased cancer risk in Asians (CC VS TT: OR = 0.29, 95%CI = 0.08-0.99). Our results suggest that Q576R, I75V and S503P may be associated with a decreased cancer risk for certain types of cancers and in some specific ethnic groups. Future case-control studies with large sample size are needed to evaluate these associations in detail.

• Journal of Microbiology and Biotechnology
• /
• v.7 no.4
• /
• pp.237-241
• /
• 1997

Two isolated strains, Comamonas testosteroni CPW301 and Arthrobacter ureafaciens CPR706, were able to use 4-chlorophenol (4-CP) as a sole carbon and energy source. CPW301 was found to degrade 4-CP via a meta-cleavage pathway in which the chloro-substituent was eliminated even when 4-chlorocatechol was cleaved by the catechol 2, 3-dioxygenase. In contrast, CPR706 removed chloride from 4-CP prior to the ring-fission reaction, producing hydroquinone as a transient intermediate during 4-CP degradation. CPR706 exhibited much higher tolerance for 4-CP than CPW301, which was indicated by the maximum degradable concentration and degradation rate.

• Journal of Microbiology and Biotechnology
• /
• v.8 no.1
• /
• pp.96-100
• /
• 1998

Pseudomonas sp. S-47 degraded 4-chlorobenzoate (4CBA) to 4-chlorocatechol (4CC) that was subsequently ring-cleaved to form 5-chloro-2-hydroxymuconic semialdehyde. These intermediate compounds were identified by GC-mass spectrometry and UV-visible spectrophotometry. 5-chloro-2-hydroxymuconic acid converted from 5-chloro-2- hydroxymuconic semialdehyde (5C-2HMS) was dechlorinated to produce 2-hydroxypenta-2,4-dienoic acid (2HP-2,4DA) by the strain. These results indicate that Pseudomonas sp. S-47 degrades 4CBA to 2HP-2,4DA via a novel pathway including the meta-cleavage of 4CC and dechlorination of 5C-2HMS.

• Asian Pacific Journal of Cancer Prevention
• /
• v.13 no.4
• /
• pp.1355-1360
• /
• 2012

Background: The cell cycle checkpoint kinase 2 (CHEK2) gene I157T variant may be associated with an increased risk of breast cancer, but it is unclear whether the evidence is sufficient to recommend testing for the mutation in clinical practice. Materials and Methods: We systematically searched PubMed, Embase, Elsevier and Springer for relevant articles published before Nov 2011. Summary odds ratio (OR) and 95% confidence interval (95% CI) incidence rates were calculated using a random-effects model with STATA (version 10.0) software. Results: A total of fifteen case-control studies, including 19,621 cases and 27,001 controls based on the search criteria, were included for analysis. A significant association was found between carrying the CHEK2 I157T variant and increased risk of unselected breast cancer (OR = 1.48, 95% CI = 1.31-1.66, P < 0.0001), familial breast cancer (OR = 1.48, 95% CI = 1.16-1.89, P < 0.0001), and early-onset breast cancer (OR = 1.47, 95% CI = 1.29-1.66, P < 0.0001). We found an even stronger significant association between the CHEK2 I157T C variant and increased risk of lobular type breast tumors (OR = 4.17, 95% CI = 2.89-6.03, P < 0.0001). Conclusion: Our research indicates that the CHEK2 I157T variant may be another important genetic mutation which increases risk of breast cancer, especially the lobular type.

• Asian Pacific Journal of Cancer Prevention
• /
• v.14 no.11
• /
• pp.6681-6686
• /
• 2013

Background: Fatal adverse events (FAEs) have been reported with sorafenib, a vascular endothelial growth factor receptor kinase inhibitor (VEGFR TKI). We here performed an up-to-date and detailed meta-analysis to determine the overall risk of FAEs associated with sorafenib. Methods: Databases, including PubMed, Embase and Web of Science, and abstracts presented at the American Society of Clinical Oncology annual meetings were searched to identify relevant studies. Eligible studies included randomized controlled trials evaluating sorafenib effects in patients with all malignancies. Summary incidence rates, relative risks (RRs), and 95% confidence intervals (CIs) were calculated for FAEs. In addition, subgroup analyses were performed according to tumor type and therapy regimen. Results: 13 trials recruiting 5,546 patients were included in our analysis. The overall incidence of FAEs with sorafenib was 1.99% (95%CI, 0.98-4.02%). Patients treated with sorafenib had a significantly increased risk of FAEs compared with patients treated with control medication, with an RR of 1.77 (95%CI 1.25-2.52, P=0.001). Risk varied with tumour type, but appeared independent of therapy regimen. A significantly increased risk of FAEs was observed in patients with lung cancer (RR 2.26; 95% CI 1.03-4.99; P= 0.043) and renal cancer (RR 1.84; 95% CI 1.15-2.94; P= 0.011). The most common causes of FAEs were hemorrhage (8.6%) and thrombus or embolism (4.9%). Conclusions: It is important for health care practitioners to be aware of the risks of FAEs associated with sorafenib, especially in patients with renal and lung cancer.